BMO Capital Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $24
BMO Capital Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $24
BMO Capital維持Acrivon Therapeutics的跑贏大盤,將目標股價下調至24美元
BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and lowers the price target from $25 to $24.
BMO Capital分析師埃策·達魯特維持Acrivon Therapeutics(納斯達克股票代碼:ACRV)跑贏大盤,並將目標股價從25美元下調至24美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。